Baxter Hlthcare Company Profile

✉ Email this page to a colleague

What is the competitive landscape for BAXTER HLTHCARE, and what generic alternatives to BAXTER HLTHCARE drugs are available?

BAXTER HLTHCARE has two hundred and eighteen approved drugs.

There are sixteen US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.

There are thirty-seven patent family members on BAXTER HLTHCARE drugs in thirteen countries and three hundred supplementary protection certificates in fifteen countries.

Summary for Baxter Hlthcare

International Patents:	37
US Patents:	16
Tradenames:	330
Ingredients:	129
NDAs:	218

Drugs and US Patents for Baxter Hlthcare

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	PLASMA-LYTE 56 IN PLASTIC CONTAINER	magnesium acetate tetrahydrate; potassium acetate; sodium chloride	INJECTABLE;INJECTION	019047-001	Jun 15, 1984		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Baxter Hlthcare	DEXTROSE 5% IN PLASTIC CONTAINER	dextrose	INJECTABLE;INJECTION	016673-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Baxter Hlthcare	CEFTRIAXONE IN PLASTIC CONTAINER	ceftriaxone sodium	INJECTABLE;INJECTION	065224-002	Aug 23, 2005		RX	No	Yes		⤷ Try a Trial				⤷ Try a Trial
Baxter Hlthcare	DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)	dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	018037-003	Approved Prior to Jan 1, 1982	AP	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Baxter Hlthcare	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate	INJECTABLE;INJECTION	019367-005	Apr 5, 1985	AP	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Baxter Hlthcare	TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019520-010	Sep 23, 1988		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Baxter Hlthcare	TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019520-005	Sep 23, 1988		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Baxter Hlthcare

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-005	Jan 27, 2003	6,310,094*PED	⤷ Try a Trial
Baxter Hlthcare	BREVIBLOC	esmolol hydrochloride	INJECTABLE;INJECTION	019386-003	Aug 15, 1988	5,017,609*PED	⤷ Try a Trial
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-004	Oct 10, 1992	4,882,452	⤷ Try a Trial
Baxter Hlthcare	MESNEX	mesna	INJECTABLE;INTRAVENOUS	019884-001	Dec 30, 1988	4,220,660	⤷ Try a Trial
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998	8,133,883	⤷ Try a Trial
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	4,762,856*PED	⤷ Try a Trial
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-004	Oct 10, 1992	4,220,660	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Inhalation	99.90%	➤ Subscribe	2008-09-11
➤ Subscribe	Injection	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags	➤ Subscribe	2014-01-31

International Patents for Baxter Hlthcare Drugs

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	031355	⤷ Try a Trial
European Patent Office	3363430	⤷ Try a Trial
Japan	6039721	⤷ Try a Trial
Canada	3170514	⤷ Try a Trial
New Zealand	589290	⤷ Try a Trial
China	114053423	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2021183752	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2957286	122018000145	Germany	⤷ Try a Trial	PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719
0933372	SPC/GB08/018	United Kingdom	⤷ Try a Trial	PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
0268956	SPC/GB98/040	United Kingdom	⤷ Try a Trial	PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
0306228	SPC/GB01/002	United Kingdom	⤷ Try a Trial	PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
1586316	C 2011 004	Romania	⤷ Try a Trial	PRODUCT NAME: BROMFENAC, SARURILE SI HIDRATII SAI ACCEPTABILI FARMACEUTICACID 2-[2-AMINO-3-(4-BROMOBENZOIL)FENILACETIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/692/001; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/692/001; DATE OF FIRST AUTHORISATION IN EEA: 20110518
1948158	2016C/026	Belgium	⤷ Try a Trial	PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS SACUBITRIL VALSARTAN NATRIUMZOUT COMPLEX, I.E. TRINATRIUM (3-((1S,3R)-1-BIFENYL-4-YLMETHYL-3-ETHOXYCARBONIL-1-BUTYLCARBAMOYL)PROPIONAAT-(S)-3'-METHYL-2'-(PENTANOYL(2-(TETRAZOL-5-YLATE)BIFENYL-4'-YLMETHYL)AMINO)BUTYRAAT)HEMIPENTAHYDRAAT; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
2187879	SPC/GB17/031	United Kingdom	⤷ Try a Trial	PRODUCT NAME: 1-CHLORO-4-(SS-D-GLUCOPYRANOS-1-YL)-2-(4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL)-BENZENE (I.E. EMPAGLIFLOZIN) IN COMBINATION WITH 1-((4 METHYL-QUINAZOLIN-2-YL)METHYL)-3-METHYL-7-(2-BUTYN-1-YL)-8-(3-(R)-AMINO-PIPERIDIN-1-YL)-XANTHINE (I.E. LINAGLIPTIN) OR A P; REGISTERED: UK PLGB 14598/0191 (GB) 20161115; UK EU/1/16/1146/014(NI) 20161115; UK EU/1/16/1146/015(NI) 20161115; UK EU/1/16/1146/016(NI) 20161115; UK EU/1/16/1146/017(NI) 20161115; UK EU/1/16/1146/018(NI) 20161115; UK EU/1/16/1146/007(NI) 20161115; UK EU/1/16/1146/001(NI) 20161115; UK EU/1/16/1146/013(NI) 20161115; UK EU/1/16/1146/002(NI) 20161115; UK EU/1/16/1146/003(NI) 20161115; UK EU/1/16/1146/004(NI) 20161115; UK...
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for Baxter Hlthcare

Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing